Bristol Myers trial revisions shake confidence in new class of fibrosis drugs

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 30 Sept, 16:22 UTC

A spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol’s admilparant — though it’s unclear whether the drug was to blame.

science

Sources

• T2Bristol Myers trial revisions shake confidence in new class of fibrosis drugsBioPharma Dive / Healthcare Dive / MedTech Dive30 Sept, 16:22